Organoids in 2D showed increased sensitivity to MEK inhibition using the US Food and Drug Administration (FDA)-approved inhibitor trametinib (Figures 3N and S7E), demonstrating that particular cancer states have specific therapeutic vulnerabilities. The gene discussed is MAP2K7; the disease is cancer.